CN114159333A - Muscle foundation liquid and preparation method thereof - Google Patents
Muscle foundation liquid and preparation method thereof Download PDFInfo
- Publication number
- CN114159333A CN114159333A CN202111675624.XA CN202111675624A CN114159333A CN 114159333 A CN114159333 A CN 114159333A CN 202111675624 A CN202111675624 A CN 202111675624A CN 114159333 A CN114159333 A CN 114159333A
- Authority
- CN
- China
- Prior art keywords
- skin
- phase
- muscle
- percent
- deionized water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000007788 liquid Substances 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 43
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 38
- 239000008367 deionised water Substances 0.000 claims abstract description 37
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 37
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 36
- 150000004676 glycans Chemical class 0.000 claims abstract description 25
- 239000003906 humectant Substances 0.000 claims abstract description 25
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 25
- 239000005017 polysaccharide Substances 0.000 claims abstract description 25
- 241000195619 Euglena gracilis Species 0.000 claims abstract description 24
- 102000008186 Collagen Human genes 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 22
- 229920001436 collagen Polymers 0.000 claims abstract description 22
- 235000011187 glycerol Nutrition 0.000 claims abstract description 15
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000004359 castor oil Substances 0.000 claims abstract description 4
- 235000019438 castor oil Nutrition 0.000 claims abstract description 4
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003755 preservative agent Substances 0.000 claims abstract description 3
- 230000002335 preservative effect Effects 0.000 claims abstract description 3
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 3
- 239000000230 xanthan gum Substances 0.000 claims abstract description 3
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 3
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 3
- 239000012530 fluid Substances 0.000 claims description 35
- 230000003020 moisturizing effect Effects 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 241001494479 Pecora Species 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 210000002826 placenta Anatomy 0.000 claims description 15
- 241000219925 Oenothera Species 0.000 claims description 12
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- 108010058643 Fungal Proteins Proteins 0.000 claims description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 10
- 229960005323 phenoxyethanol Drugs 0.000 claims description 10
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000007689 inspection Methods 0.000 claims description 7
- 239000011570 nicotinamide Substances 0.000 claims description 7
- 229960003966 nicotinamide Drugs 0.000 claims description 7
- 235000005152 nicotinamide Nutrition 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 6
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 4
- 235000003310 Adansonia Nutrition 0.000 claims description 4
- 241000982340 Adansonia Species 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- CCLARULDIPFTCP-BOYHRMMASA-N (2r,3r,4r,5s)-heptane-1,2,3,4,5,6-hexol Chemical compound CC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CCLARULDIPFTCP-BOYHRMMASA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- -1 polyquaternium-51 Polymers 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 24
- 239000004909 Moisturizer Substances 0.000 abstract description 5
- 230000001333 moisturizer Effects 0.000 abstract description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 119
- 230000000052 comparative effect Effects 0.000 description 60
- 230000037303 wrinkles Effects 0.000 description 37
- 230000037394 skin elasticity Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 30
- 239000006210 lotion Substances 0.000 description 30
- 210000000434 stratum corneum Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 18
- 230000003203 everyday effect Effects 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 125000001453 quaternary ammonium group Chemical class 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- 230000037336 dry skin Effects 0.000 description 5
- 230000037393 skin firmness Effects 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 4
- 241001474374 Blennius Species 0.000 description 4
- 206010050637 Skin tightness Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229940031722 methyl gluceth-20 Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 244000237986 Melia azadirachta Species 0.000 description 3
- 235000013500 Melia azadirachta Nutrition 0.000 description 3
- 240000006079 Schisandra chinensis Species 0.000 description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000012634 optical imaging Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 240000000233 Melia azedarach Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229940045761 evening primrose extract Drugs 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 229940065115 grapefruit extract Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 241001485474 Adonis amurensis Species 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000200287 Gymnodinium Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical group OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Cosmetics (AREA)
Abstract
The application relates to the technical field of cosmetics, and particularly discloses a muscle foundation solution and a preparation method thereof, wherein the muscle foundation solution comprises the following components in percentage by weight: the balance of deionized water; phase A: 1, 2-pentanediol, 1, 2-hexanediol, a first humectant, xanthan gum, a preservative and glycerol; phase B: acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, deionized water, phase C: a second humectant; phase D: butylene glycol, PEG-60 hydrogenated castor oil, ethylhexyl glycerin; phase E: fructus Schisandrae extract, first antioxidant, second antioxidant, third antioxidant, first skin conditioner, and second skin conditioner; a third skin conditioner, a fourth skin conditioner, a third moisturizer; the first antioxidant contains hydrolyzed collagen; the second antioxidant comprises radix Oenotherae Erythrosepalae extract; the second skin conditioner contains euglena gracilis polysaccharide; the muscle foundation liquid has good tightening and anti-wrinkle effects.
Description
Technical Field
The application relates to the technical field of cosmetics, in particular to a muscle foundation solution and a preparation method thereof.
Background
The stratum corneum is the outermost part of the epidermis of the human body, and can resist external stimuli, prevent the extravasation of body fluids and be an important protective barrier for the human body. When the skin barrier is damaged, the external cuticle can fall off abnormally naturally, so that the waste cuticle is accumulated and hardened, the skin is rough, wrinkles are generated, and the absorption of skin care products is influenced.
With time, muscle fluid gradually walks into the general visual field. Muscle lotion is a skin care product containing both hydrophilic and lipophilic components, which is usually applied after cleansing and toning. The skin foundation liquid can be better absorbed by the skin by simultaneously breaking the moisture and the oil in other skin care products, simultaneously regulates the metabolism of cutin, moisturizes and moistens the skin, and has certain skin care effect.
Through the related technology, a certain amount of salicylic acid is usually added into the traditional skin care product to condition the keratin, but after the salicylic acid is used for a certain time, the cuticle can be thinned, the skin is damaged, the problem of insufficient tightness is caused, and the problems of wrinkles, dry skin and the like are easy to occur.
Disclosure of Invention
In order to enhance the firming and anti-wrinkle effects of the muscle base fluid on the skin, the application provides the muscle base fluid and a preparation method thereof.
In a first aspect, the present application provides a muscle fluid base, which adopts the following technical scheme:
a muscle foundation solution comprises the following components in percentage by weight:
the balance of deionized water;
phase A:
0.4-5% of 1, 2-pentanediol;
0.3 to 0.8 percent of 1, 2-hexanediol;
0.22 to 8.7 percent of first humectant;
0.01 to 0.2 percent of xanthan gum;
0.32 to 0.7 percent of preservative;
3.98-9.95% of glycerin;
phase B:
acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer 0.15-0.4%;
4.4 to 9.5 percent of deionized water;
and C phase:
1.45 to 3.3 percent of second humectant;
phase D:
0.1-5% of butanediol;
PEG-60 hydrogenated castor oil 0.01-0.3%;
0.02-0.1% of ethylhexyl glycerol;
phase E:
fructus Schisandrae extract 0.001-1%;
0.001 to 0.5 percent of first antioxidant;
0.01-4% of second antioxidant;
0.01-3% of third antioxidant;
0.01-1% of a first skin conditioner;
0.01-4% of a second skin conditioner;
0.01-3% of a third skin conditioner;
fourth skin conditioner 0.01-4%;
0.01-3% of a third humectant;
the first antioxidant consists of 52-58 wt% of hydrolyzed collagen, 0.08-0.12 wt% of ethylhexyl glycerol, 3.5-4.5 wt% of butanediol, 0.8-1 wt% of phenoxyethanol and the balance of deionized water;
the second antioxidant consists of 0.09-0.11 wt% of evening primrose root extract, 0.08-0.12 wt% of citric acid, 0.15-0.25 wt% of potassium sorbate, 0.8-1.2 wt% of phenoxyethanol, 48-53 wt% of butanediol and the balance of deionized water;
the first skin conditioner consists of 0.2 to 0.3 weight percent of hydrolyzed placenta (sheep) extract and the balance of deionized water;
the second skin conditioner consists of euglena gracilis polysaccharide, polyquaternium-51, agar, phenoxyethanol, glycerol and the balance of deionized water.
By adopting the technical scheme, the hydrolyzed collagen in the first antioxidant in the phase E is collagen containing more amino acids, and can improve the moisture supply of skin, thereby protecting the stratum corneum, tightening the skin elasticity, promoting the metabolism and inhibiting the generation of wrinkles; meanwhile, the chemotaxis of hydrolyzed collagen on fibroblasts stimulates the growth of the fibroblasts of the skin, obviously increases the density of the fibroblasts, increases the elasticity of the skin, and is also beneficial to improving fine wrinkles and deep wrinkles of the skin. The radix Oenotherae Erythrosepalae extract has good effect in eliminating superoxide radical, and can be combined with citric acid as fruit acid to promote cutin regeneration and improve rough skin. After the first antioxidant and the second antioxidant are matched, the composition is beneficial to jointly protecting the cuticle, tightening the skin elasticity and endowing the muscle base fluid with better tightening and anti-wrinkle effects. The third antioxidant also has certain antioxidant effect, so as to improve the effects of muscle fluid tightening and wrinkle resistance together with hydrolyzed collagen and evening primrose extract.
The hydrolyzed placenta (sheep) extract is a polypeptide protein, has good antioxidant and anti-aging effects, has certain anti-wrinkle effect, and can be used together with hydrolyzed collagen which is a polypeptide substance to further enhance the effects of tightening and resisting wrinkle of muscle base fluid. The Euglena gracilis polysaccharide is a specific component of Euglena, and has effects of keeping moisture, resisting oxidation, and activating skin; the polyquaternium-51 is mainly used as a humectant and a film forming agent, and after the polyquaternium-51 and the humectant are combined, the anti-wrinkle and skin-activating effects of the muscle foundation fluid are promoted. After the hydrolyzed placenta (sheep) extract and the second skin conditioner are matched, more nutrition is supplied to the skin, and the effects of tightening and resisting wrinkles of the muscle base fluid are promoted.
The schisandra extract has the function of enhancing cellular immunity, has obvious anti-free radical effect and can play a role of anti-aging by changing the enzyme activity; in addition, schizandrin in the schisandra chinensis extract has an antioxidant effect, and is matched with each antioxidant and skin conditioner after being mixed, so that the effects of tightening and resisting wrinkles of muscle base fluid are further enhanced.
The components such as the first humectant, the 1, 2-pentanediol and the like in the phase A are used for moisturizing, thickening and the like; the acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer in the B phase mainly plays a role in film forming and thickening; the second humectant, the first humectant and the third humectant in the phase C jointly improve the moisturizing effect of the muscle foundation solution; PEG-60 hydrogenated castor oil, ethylhexyl glycerin and other components in the phase D improve the moisturizing and stabilizing effects of the muscle base fluid. After the substances are mixed with the phase E, the dissolution and the mixing of the phase E are promoted, and meanwhile, all components in the phase E fully play a role, so that the firming and anti-wrinkle effects of the muscle base fluid are enhanced.
In conclusion, the components of the antioxidant, such as hydrolyzed collagen, evening primrose extract, citric acid and the like, enhance the effects of tightening, resisting wrinkles and preserving moisture of the muscle base fluid; the skin conditioner comprises hydrolyzed placenta (sheep) extract, euglena gracilis polysaccharide, polyquaternium-51, fructus Schisandrae extract, etc., and simultaneously phase A, phase B, phase C, and phase D are added to obtain the skin foundation solution with good tightening and anti-wrinkle effects.
Preferably, the third antioxidant consists of the following components in percentage by weight:
0.2 to 0.25 percent of hydrolyzed yeast protein;
0.4 to 0.6 percent of sodium benzoate;
25-35% of glycerol;
the balance of deionized water.
By adopting the technical scheme, the hydrolyzed yeast protein can effectively permeate into the bottom layer of the skin, so that the normal growth of cells in the skin is promoted, the stratum corneum is protected, and meanwhile, the skin cells can be supported, and the effects of fading fine wrinkles and stretching coarse wrinkles are achieved; meanwhile, the hydrolyzed yeast protein is easy to be absorbed by the skin, and helps to increase the skin firmness. When combined with hydrolyzed collagen in the first antioxidant and evening primrose root extract, the composition can further enhance the effects of tightening skin with muscle base fluid and reducing skin wrinkles.
Preferably, the second skin conditioner consists of the following components in percentage by weight:
euglena gracilis polysaccharide 2.2-2.8%;
4-6% of polyquaternium-51;
0.4 to 0.6 percent of phenoxyethanol;
2.2 to 2.8 percent of agar;
40-50% of glycerol;
the balance of deionized water.
By adopting the technical scheme, the proportion of euglena gracilis polysaccharide and polyquaternium-51 in the second skin conditioner is preferably selected, so that the components in the second skin conditioner are matched, and the firming and anti-wrinkle effects of the skin base solution are further improved.
Preferably, the third skin conditioning agent consists of the following components in percentage by weight:
0.7-0.9% of cortex Meliae extract;
0.7-0.8% of maltodextrin;
75-85% of glycerol;
the balance of deionized water.
By adopting the technical scheme, the African chinaberry bark extract has certain effects of astringing skin pores and nourishing skin, and after being matched with maltodextrin, the stability of the third skin conditioner is improved, and meanwhile, the skin is tightened and the skin is kept moist. Meanwhile, the African chinaberry bark extract and the hydrolyzed placenta (sheep) extract are synergistically matched, so that the skin quality is improved, and the anti-wrinkle effect is improved.
Preferably, the fourth skin conditioning agent consists of the following components in percentage by weight:
0.8-1.2% of Adansonia dubia seed extract;
1.4 to 1.8 percent of phenoxyethanol;
28-32% of glycerol;
the balance of deionized water.
By adopting the technical scheme, the Adansonia dubia seed extract not only has a certain moisturizing effect, but also has an antioxidant effect, and can also increase skin elasticity; the fourth skin conditioner contains Herbaea Obliqua seed extract and hydrolyzed placenta (sheep) extract, and has effects of protecting skin cuticle, and improving skin foundation tightening and wrinkle resisting effects.
Preferably, the components of the first humectant and the weight percentage of each component in the total amount of the muscle base fluid are as follows:
0.1-4% of nicotinamide;
0.1-4% of methyl glucitol polyether-20;
0.01 to 0.5 percent of dipotassium glycyrrhizinate;
0.01 to 0.2 percent of sodium hyaluronate.
By adopting the technical scheme, the nicotinamide in the first moisturizing agent is a derivative of vitamin b3, and has the effects of resisting aging, repairing, replenishing water and moisturizing; the sodium hyaluronate and the methyl gluceth-20 can promote the moisturizing effect, accelerate the cell metabolism, accelerate the stratum corneum circulation, contribute to the synthesis of collagen and slow the generation of wrinkles. The dipotassium glycyrrhizinate in the first humectant can prevent skin from being sensitive to irritation, and improve skin elasticity.
Preferably, the components of the second humectant and the weight percentage of each component in the total amount of the muscle foundation fluid are as follows:
arginine 0.15-0.4%;
1.3 to 2.9 percent of deionized water.
By adopting the technical scheme, the arginine is a basic amino acid, has a synergistic effect with the euglena gracilis polysaccharide, keeps skin moisture, smoothes skin and protects the stratum corneum, thereby further improving the elasticity of the skin and reducing the loss of the skin moisture.
Preferably, the third humectant consists of 1-1.4 wt% of sodium polyglutamate, 15-25 wt% of butanediol and the balance of deionized water.
By adopting the technical scheme, the sodium polyglutamate has certain moisturizing and stabilizing effects, and the effects of the first moisturizing agent, the second moisturizing agent, hydrolyzed collagen and the like, so that the stratum corneum is protected, the skin is promoted to absorb moisture, and the skin elasticity is kept.
In a second aspect, the present application provides a method for preparing a muscle base fluid, which adopts the following technical scheme:
a preparation method of a muscle base fluid comprises the following preparation steps:
s1, mixing the components of the phase A, heating to 75-80 ℃, and homogenizing and stirring to obtain a first mixture;
s2, mixing the components of the phase B, adding the mixture into the first mixture after uniformly mixing, homogenizing and stirring, cooling to 55-65 ℃ after uniformly stirring, and obtaining a second mixture;
s3, mixing the components in the phase C, adding the mixture into the second mixture after uniformly mixing, uniformly stirring, cooling to 40-50 ℃, adding the phase D and the phase E, and continuously and uniformly mixing to obtain a primary muscle base solution;
and S4, carrying out primary inspection, defoaming and filtering, discharging, secondary inspection, transferring and filling on the primary muscle base fluid product to obtain a finished muscle base fluid product.
By adopting the technical scheme, in the step S1, the phase A components are mixed firstly, and the homogeneity degree of the components is improved by heating; and adding the phase B component, mixing and cooling, and conveniently adding the phase C to prevent the effect of the second humectant from being damaged due to higher temperature. Then, the temperature is continuously reduced to 40-50 ℃, and the phase D and the phase E are added, so that the components of the phase E are fully fused, and the problem that the efficacy of the main component of the phase E is reduced due to overhigh temperature is also solved. And finally, obtaining the muscle base fluid with good tightening and anti-wrinkle effects and moisturizing effects through the steps of inspection, filtration and the like.
Preferably, in step S3, after the temperature is reduced to 40-45 ℃, phase D and phase E are added and mixed uniformly.
By adopting the technical scheme, the system temperature when the phase D and the phase E are added is preferably selected, so that the tightening anti-wrinkle effect of the main components is effectively kept while the uniform mixing of the components is ensured, and the tightening anti-wrinkle and moisturizing effects of the muscle foundation fluid are further enhanced.
In summary, the present application has the following beneficial effects:
1. in the present application, hydrolyzed collagen in a first antioxidant, an evening primrose root extract in a second antioxidant, is used; the hydrolyzed placenta (sheep) extract in the first skin conditioner, the euglena gracilis polysaccharide in the second skin conditioner, the polyquaternium-51 and the like are matched together, and the multiple antioxidants, the skin conditioners and the schisandra chinensis extract are used for enhancing the effects of tightening, resisting wrinkles and keeping moisture of the muscle foundation liquid together.
2. In the application, the hydrolyzed yeast protein is selected as the main component of the third antioxidant, and the weight ratio of the second skin conditioner is preferably selected, so that the euglena gracilis polysaccharide and the polyquaternium-51 are better matched, and the effects of firming and anti-wrinkle of the muscle foundation fluid are further improved. The cortex meliae extract is selected as the main component of the third skin conditioner, the Adonis amurensis seed extract is selected as the main component of the fourth skin conditioner, and then the cortex meliae extract is further matched with the first skin conditioner and the second skin conditioner, so that the effects of moisturizing, tightening and wrinkle resisting are achieved.
3. In the application, the nicotinamide and the methyl glucitol polyether-20 are selected as main components of the first moisturizing agent, so that the moisturizing and anti-wrinkle effects of the muscle base fluid are enhanced; arginine is used as a main component of the second humectant, and after the arginine is cooperated with euglena gracilis polysaccharide, the elasticity of skin is improved and the water loss of skin is reduced while the moisture is preserved.
Detailed Description
The present application is described in further detail below.
Examples
Example 1A muscle foundation comprising the specific components and weights shown in Table 1 was prepared by the following steps:
s1, mixing the components of the phase A, heating to 80 ℃, and homogenizing and stirring to obtain a first mixture;
s2, mixing the components of the phase B, adding the mixture into the first mixture after uniformly mixing, homogenizing and stirring, cooling to 65 ℃ after uniformly stirring, and obtaining a second mixture;
s3, mixing the components in the phase C, adding the mixture into the second mixture after uniformly mixing, uniformly stirring, cooling to 50 ℃, adding the phase D and the phase E, and continuously and uniformly mixing to obtain a primary muscle base solution;
and S4, carrying out primary inspection, defoaming and filtering, discharging, secondary inspection, transferring and filling on the primary muscle base fluid product to obtain a finished muscle base fluid product.
Example 2A muscle foundation differs from example 1 in that heating to 75 ℃ in step S1, cooling to 55 ℃ in step S2, and cooling to 35 ℃ in step S3, and the specific components and weights included are shown in Table 1.
Example 3A muscle base solution, which differs from example 1 in that the third antioxidant, which still was 0.01kg, consisted of 0.2% by weight of hydrolysed yeast protein, 0.4% of sodium benzoate, 35% of glycerol and the balance deionized water.
Example 4A muscle base solution, different from example 1, was obtained in that the third antioxidant, consisting of 0.25% by weight of hydrolyzed yeast protein, 0.6% by weight of sodium benzoate, 25% by weight of glycerol and the balance deionized water, remained at 0.01 kg.
Examples 5-6A muscle base solution differs from example 4 in the composition and weight ratio of the second skin conditioning agent, and the specific components and weights included are as shown in Table 1.
Examples 7-8A muscle base solution differs from example 6 in that the third skin conditioning agent has different components and weight ratios, and the specific components and weights included are as shown in Table 1.
Examples 9-10A muscle base solution differs from example 8 in that the fourth skin conditioning agent has different components and weight ratios, and the specific components and weights included are as shown in Table 1.
Example 11A muscle foundation differing from example 10 in that the first moisturizing agent was used in an amount of 4.31kg and consisted of 0.1kg of nicotinamide, 4kg of methyl gluceth-20, 0.01kg of dipotassium glycyrrhizinate and 0.2kg of sodium hyaluronate.
Example 12A muscle foundation differing from example 11 in that the first moisturizing agent was used in an amount of 4.61kg and consisted of 4kg of niacinamide, 0.1kg of methyl gluceth-20, 0.5kg of dipotassium glycyrrhizinate and 0.01kg of sodium hyaluronate.
Example 13A muscle foundation differs from example 12 in that the second moisturizer is present in an amount of 1.7kg and consists of 0.4kg arginine and 1.3kg deionized water.
Example 14A muscle foundation differs from example 13 in that the second moisturizer is present in an amount of 3.05kg and the second moisturizer consists of 0.15kg arginine and 2.9kg deionized water.
Example 15A muscle foundation differs from example 14 in that the third humectant is present in an amount of 0.01kg and consists of 1% by weight of sodium polyglutamate, 15% by weight of butylene glycol, and the balance deionized water.
Example 16A muscle foundation differs from example 14 in that the third moisturizer is present in an amount of 0.01kg and consists of 1.4% by weight of sodium polyglutamate, 25% by weight of butylene glycol, and the balance deionized water.
Example 17A muscle base solution different from example 16 in that, in step S3, after cooling to 45 ℃, phase D and phase E were added and mixed successively.
Example 18A muscle base solution different from example 16 in that, in step S3, after cooling to 40 ℃, phase D and phase E were added and mixed successively.
Examples 19-20A muscle fluid base, which differs from example 18 in that the specific components and weights included are as shown in Table 1.
TABLE 1 specific Components and weights for examples 1-2, examples 5-10, and examples 19-20
Comparative example
Comparative example 1A muscle base solution, which is different from example 1 in that an equal amount of evening primrose root extract was used instead of hydrolyzed collagen.
Comparative example 2A muscle base solution, which is different from example 1 in that an equal amount of hydrolyzed collagen was used instead of the evening primrose root extract.
Comparative example 3A muscle base solution was distinguished from example 1 in that an equal amount of evening primrose root extract was used instead of citric acid.
Comparative example 4A muscle base solution, which is different from example 1 in that an equal amount of grapefruit extract was used instead of evening primrose root extract and hydrolyzed collagen.
Comparative example 5A muscle base solution was prepared, which was different from example 1 in that an equal amount of deionized water was used instead of the hydrolyzed placenta (sheep) extract.
Comparative example 6A muscle foundation differing from example 1 in that the same amount of extract of seaweed of the lobular algae was used instead of the polysaccharide of Euglena gracilis.
Comparative example 7A muscle foundation differing from example 1 in that the same amount of euglena gracilis polysaccharide was used instead of polyquaternium-51.
Comparative example 8A muscle foundation differing from example 1 in that the same amount of extract of seaweed of the lobular algae was used instead of the polysaccharide of Euglena gracilis and polyquaternium-51.
Comparative example 9A muscle foundation different from example 1 in that an equal amount of deionized water was used instead of the hydrolyzed placenta (sheep) extract and an equal amount of the extract of seaweed of lobular algae was used instead of the polysaccharide of Euglena gracilis and the polyquaternium-51.
Comparative example 10A muscle foundation differing from example 1 in that the evening primrose root extract and hydrolyzed collagen were replaced with equal amounts of grapefruit extract, the hydrolyzed placenta (sheep) extract was replaced with equal amounts of deionized water, and the euglena gracilis polysaccharide was replaced with equal amounts of seaweed extract deionized water.
Detection method
Experiment one: skin tightening Performance and skin elasticity test
Experimental samples: muscle base solutions of examples 1-20 and comparative examples 1-10.
An experimental instrument: skin elasticity tester Cutometer MPA 580.
The experimental subjects involved 124 healthy Chinese females with no obvious trauma and disease to the face, lack of moistening the face, dry skin and no allergic disease in 25-45 years old were recruited, one group was included in 4 persons, 31 groups were included, the first 30 groups of experimental groups corresponded to examples 1-20 and comparative examples 1-10, respectively, and the last group was blank.
The experimental method comprises the following steps:
(1) after the subject cleans the face and waits for 20min quietly, the skin elasticity tester Cutomer MPA580 detects the skin tightness parameter F4 value and the skin elasticity R2 value of the right corner of the right eye of the subject respectively; the test sites are tested for 5 times, the maximum value and the minimum value are cut off, and the rest values are averaged to respectively obtain the F4 value and the R2 value of the skin tightness parameter at the D0 (namely the F4 value and the R2 value of the skin elasticity parameter at the beginning of the experimental subject);
(2) experimental groups: after cleansing, the subjects applied 1.5mL of lotion (hereinafter, all lotions used are from non-printing good base lotion refreshing 200mL) to the whole face at 8 am every day, and applied 1mL of skin base solution to the whole face after 3 min. At 8 pm, 1.5mL of the lotion of comparative example 11 was applied to the whole face every day, and after 3min, 1mL of the muscle foundation solution was applied to the whole face for an experimental period of 28 days.
Blank group: after the face is cleaned, 1.5mL of lotion is only applied to the whole face at 8 am every day. 1.5mL of toning lotion is smeared on the whole face at 8 o' clock every day in the evening, and the experimental period is 28 days.
(3) Respectively detecting a skin tightness parameter F4 value and a skin elasticity R2 value of D28 at the right canthus position of the subject by using a skin elasticity tester Cutomer MPA 580; testing the tested part for 5 times, rounding off the maximum value and the minimum value, and averaging the rest values to obtain a skin tightness parameter F4 value and a skin elasticity R2 value of D28; and the rate of change of the skin tightening parameter F4 value (the skin tightening parameter F4 value of D28-the skin tightening parameter F4 value of D0)/the skin tightening parameter F4 value of D0 x 100% was calculated for each set of experimental samples.
The rate of change in the skin elasticity R2 value (skin elasticity R2 value of D28-skin elasticity R2 value of D0)/skin elasticity R2 value of D0 × 100%;
the experimental results of examples 1-20, comparative examples 1-10 and the blank were obtained using the experimental methods described above, respectively.
The experimental results are as follows: the results of the compact experiments for examples 1-20, comparative examples 1-10, and the blank are shown in table 2; the results of the elasticity tests of examples 1 to 20, comparative examples 1 to 10 and the blank group are shown in Table 3.
Second experiment, skin anti-wrinkle experiment
Experimental samples: muscle base solutions of examples 1-20 and comparative examples 1-10.
An experimental instrument: skin Rapid optical imaging System Primos CR.
The experimental subjects involved 124 healthy Chinese females with no obvious trauma and disease to the face, lack of moistening the face, dry skin and no allergic disease in 25-45 years old were recruited, one group was included in 4 persons, 31 groups were included, the first 30 groups of experimental groups corresponded to examples 1-20 and comparative examples 1-10, respectively, and the last group was blank.
The experimental method comprises the following steps:
(1) adopting a skin rapid optical imaging system Primos CR to detect the wrinkle depth of the right canthus of the experimental subject; testing the test part for 5 times, rounding off the maximum value and the minimum value, and averaging the rest values to respectively obtain the wrinkle depth (namely the initial wrinkle depth of the experimental object) at D0;
(2) experimental groups: after cleansing, the subjects applied 1.5mL of lotion (hereinafter, all lotions used are from non-printing good base lotion refreshing 200mL) to the whole face at 8 am every day, and applied 1mL of skin base solution to the whole face after 3 min. Applying 1.5mL of lotion to the whole face at 8 pm every day, and applying 1mL of muscle foundation solution to the whole face after 3min, wherein the experimental period is 28 days.
Blank group: after the face is cleaned, 1.5mL of lotion is only applied to the whole face at 8 am every day. 1.5mL of toning lotion is smeared on the whole face at 8 o' clock every day in the evening, and the experimental period is 28 days.
(3) Respectively detecting the wrinkle depth of D28 at the right canthus of the subject by using a skin rapid optical imaging system Primos CR; testing the tested part for 5 times, rounding off the maximum value and the minimum value, and averaging the rest values to obtain the wrinkle depth D28; and the change rate of each set of experimental samples, that is, the wrinkle depth change rate (wrinkle depth of D0-wrinkle depth of D28)/wrinkle depth of D0 × 100%, was calculated.
The above experimental methods were used to obtain the anti-wrinkle results for examples 1-20, comparative examples 1-10, and the blank, respectively.
The experimental results are as follows: the results of the wrinkle resistance test for examples 1 to 20, comparative examples 1 to 10, and the blank group are shown in table 4.
Experiment three: sensory evaluation test
Experimental samples: muscle base solutions of examples 1-20 and comparative examples 1-10.
The experimental subjects involved 124 healthy Chinese females with no obvious trauma and disease to the face, lack of moistening the face, dry skin and no allergic disease in 25-45 years old were recruited, one group was included in 4 persons, 31 groups were included, the first 30 groups of experimental groups corresponded to examples 1-20 and comparative examples 1-10, respectively, and the last group was blank.
The experimental method comprises the following steps:
experimental groups: after cleansing, the subjects applied 1.5mL of lotion (hereinafter, all lotions used are from non-printing good base lotion refreshing 200mL) to the whole face at 8 am every day, and applied 1mL of skin base solution to the whole face after 3 min. Applying 1.5mL of lotion to the whole face at 8 pm every day, and applying 1mL of muscle foundation solution to the whole face after 3min, wherein the experimental period is 28 days.
Blank group: after the face is cleaned, 1.5mL of lotion is only applied to the whole face at 8 am every day. 1.5mL of toning lotion is smeared on the whole face at 8 o' clock every day in the evening, and the experimental period is 28 days.
Using a sensory scoring method:
skin elasticity: 1-5 points, the better the skin elasticity, the higher the score; the lower the skin elasticity, the lower the score.
Skin firmness: 1-5 points, the firmer the skin, the higher the score; the less compact, the lower the score.
The wrinkle improvement effect is 1-5 points, and the higher the wrinkle improvement degree is, the higher the score is; the worse the wrinkle improvement, the lower the score.
Grading content: the testees of each group are scored according to the using condition, and the average value in the groups is taken as the final sensory evaluation result after scoring.
The experimental results are as follows: the results of the sensory evaluation tests of examples 1 to 20, comparative examples 1 to 10 and the blank group are shown in Table 5.
TABLE 2 results of experiments for examples 1-20, comparative examples 1-10 and blank set
TABLE 3 results of skin elasticity test for examples 1-20, comparative examples 1-10, and blank group
TABLE 4 wrinkle DEPTH TEST RESULTS FOR EXAMPLES 1-20, COMPARATIVE EXAMPLES 1-10, AND BLANKS
TABLE 5 results of experiments for examples 1-20, comparative examples 1-10 and blank set
As can be seen from the experimental data in tables 2-5, the examples 1-20 have better anti-wrinkle tightening effect and higher skin elasticity improvement; however, the comparative examples 1 to 10 have inferior firming and anti-wrinkle effects and less skin elasticity improvement degree compared to examples 1 to 20, which shows that the muscle foundation solution of the present application is useful for enhancing skin firming, anti-wrinkle and skin elasticity improvement effects. The blank group was base lotion, excluding the influence of the base lotion, and the skin base lotions of examples 1 to 20 had better protective degree of stratum corneum, had better tightening and anti-wrinkle effects, and improved skin elasticity.
As can be seen from the comparison of example 1 and comparative examples 1-4, after the hydrolyzed collagen and the evening primrose root extract are added, the tightening anti-wrinkle effect is better than that of the independently added hydrolyzed collagen and evening primrose root extract, and the skin elasticity degree is better, so that the tightening skin can be enhanced, the stratum corneum is better, the stratum corneum is helpful for the regeneration of the stratum corneum, and the generation of wrinkles is reduced. As can be seen from the comparison of example 1 and comparative examples 6-8, the euglena gracilis polysaccharide and the quaternary ammonium salt-51 are added together, so that the effects of promoting the skin foundation fluid to tighten and resist wrinkles and improving the skin elasticity are facilitated; as can be seen from comparative example 1 and comparative examples 5 to 9, the hydrolyzed placenta (sheep) extract, the euglena gracilis polysaccharide, and the quaternary ammonium salt-51 act together to supplement nutrients to the skin, promote the improvement of the skin elasticity, enhance the skin firmness, protect the stratum corneum, and reduce the generation of wrinkles. As can be seen from the comparison of example 1 with comparative example 4, and from the comparison of example 5 with comparative example 8, the skin firmness can be greatly improved, the generation of wrinkles can be reduced, and the skin elasticity can be improved after the conditioners are combined with the antioxidant.
As can be seen from comparing example 1 with examples 3-4, the addition of the hydrolyzed yeast protein in the third antioxidant resulted in more firm and elastic skin and reduced wrinkles. The results show that after the hydrolyzed yeast protein is added, the hydrolyzed yeast protein and hydrolyzed collagen are acted, and the cell growth and absorption are promoted, so that fine lines are lightened, and the skin firmness is increased. It can be seen from comparative examples 4-6 that, by optimizing the proportion of the second skin conditioner, the components in the second skin conditioner are matched, so that the firming and anti-wrinkle effects of the muscle base fluid are further improved. Comparative examples 6-8 show that the addition of the neem bark extract to the third skin conditioner synergistically improves skin elasticity while improving wrinkles by combining with the hydrolyzed placenta (sheep) extract. In comparative examples 8 to 10, it was found that the skin elasticity was increased and the skin-tightening effect of the muscle fluid was gradually improved in the fourth skin conditioner, which was the extract of the Paeonia suffruticosa seeds.
Comparative examples 10 to 12 show that the addition of the first moisturizing agent can help the synthesis of collagen in the skin, reduce the generation of wrinkles, and improve the elasticity of the skin, probably due to the effects of niacinamide and methyl gluceth-20. Comparative examples 12 to 14 show that the skin condition is improved by adding the second humectant arginine, probably because arginine can cooperate with euglena gracilis polysaccharide to retain and smooth the skin moisture, thereby further improving the skin elasticity and reducing the loss of skin moisture.
In comparative examples 16 to 18, it is understood that the heating temperature is preferably selected to sufficiently retain the effective components and further to promote the skin-tightening and anti-wrinkle effects. Comparing example 1 and examples 19-20, it can be seen that the particular components of each conditioner, and preferably the temperature during the manufacturing process, are preferred to provide a greater increase in skin elasticity and enhanced foundation firming and anti-wrinkle benefits.
Experiment four: test of Water content of skin horny layer
Experimental samples: muscle base solutions of examples 1-20 and comparative examples 1-10.
An experimental instrument: skin moisture test probe Corneometer CM 825.
The experimental subjects involved 124 healthy Chinese females with no obvious trauma and disease to the face, lack of moistening the face, dry skin and no allergic disease in 25-45 years old were recruited, one group was included in 4 persons, 31 groups were included, the first 30 groups of experimental groups corresponded to examples 1-20 and comparative examples 1-10, respectively, and the last group was blank.
The experimental method comprises the following steps:
(1) after the test object cleans the face, after waiting for 20min quietly, a skin moisture test probe Corneometer CM 825 is adopted to respectively detect the moisture content of the horny layer of the right cheek part of the test object, the test part is tested for 5 times, the maximum value and the minimum value are cut off, and the rest values are averaged to obtain the moisture content of the horny layer at D0 (namely the initial moisture content of the horny layer when the test object does not use skin care water);
(2) experimental groups: after cleansing, the subjects applied 1.5mL of lotion (hereinafter, all lotions used are from non-printing good base lotion refreshing 200mL) to the whole face at 8 am every day, and applied 1mL of skin base solution to the whole face after 3 min. Applying 1.5mL of lotion to the whole face at 8 pm every day, and applying 1mL of muscle foundation solution to the whole face after 3min, wherein the experimental period is 28 days.
Blank group: after the face is cleaned, 1.5mL of lotion is only applied to the whole face at 8 am every day. 1.5mL of toning lotion is smeared on the whole face at 8 o' clock every day in the evening, and the experimental period is 28 days.
(3) Respectively detecting the moisture content of the stratum corneum of D28 at the right cheek part of the subject by using a skin moisture test probe Corneometer CM 825; testing the test part for 5 times, discarding the maximum value and the minimum value, and averaging the rest values to obtain the moisture content of the skin stratum corneum of D28; and the change rate of each experimental sample, i.e., the change rate of stratum corneum moisture content (stratum corneum moisture content of D28-stratum corneum moisture content of D0)/stratum corneum moisture content of D0 × 100%, was calculated.
The above experimental methods were used to obtain the change rates of the water content of the horny layer using examples 1 to 20, comparative examples 1 to 10, and the blank group, respectively.
The experimental results are as follows: the results of the experiments of examples 1-20, comparative examples 1-10 and the blank are shown in Table 6.
TABLE 6 results of stratum corneum moisture content experiments of examples 1-20, comparative examples 1-10, and blank
As can be seen from the experimental data in Table 6, the stratum corneum water content growth rate of examples 1-20 was 9.85-10.72%, and that of comparative examples 1-10 was 7.22-9.71%; the moisturizing effects of examples 1-20 were better than those of comparative examples 1-10. The blank group is an experiment only using basic lotion alone, and shows that under the influence of the lotion, the muscle foundation liquid has a good moisturizing effect and can effectively protect the horny layer.
It can be seen from the comparison of example 1 and comparative examples 1 to 4 that the water content of the stratum corneum of the skin is increased by adding the hydrolyzed collagen and the evening primrose root extract, probably because the addition of both of them can supplement water to the skin and protect the stratum corneum, and also contribute to the promotion of metabolism and the acceleration of stratum corneum turnover, thereby improving the dry state of the skin. As can be seen from the comparison of example 1 and comparative examples 6-8, the skin moisture content is increased after the euglena gracilis polysaccharide and the quaternary ammonium salt-51 are added, which shows that the euglena gracilis polysaccharide and the quaternary ammonium salt-51 have good moisturizing effect; as can be seen from the comparison of example 1 and comparative examples 5-9, the addition of the hydrolyzed placenta (sheep) extract, together with the Euglena gracilis polysaccharide and the quaternary ammonium salt-51, helps to provide more nutrients to the skin and thus increases the moisture content of the skin. As can be seen from the comparison of example 1 with comparative example 4 and from the comparison of example 5 with comparative example 8, the antioxidant and the conditioner have a certain coordination effect after being combined together, so that the moisture content of the skin is greatly increased.
As can be seen from comparison of examples 1 and 3-4, the hydrolyzed yeast protein in the third antioxidant, in combination with the first antioxidant, effectively penetrates into the bottom layer of the skin, thereby promoting the absorption of moisture by the skin. Comparative examples 4-6 show that the second skin conditioner, Gymnodinium parvum polysaccharide and Quaternary ammonium salt-51, are preferred to help improve the moisturizing effect of the muscle base fluid.
Comparative examples 6-8 show that the addition of the third skin conditioner, neem bark extract, helps to moisturize the skin and enhance the moisturizing effect of the muscle fluid, probably because the combination of neem bark extract and hydrolyzed placenta (sheep) extract further moisturizes the skin and improves the moisturizing effect. Comparative examples 8 to 10 show that the extract of the seeds of Adansonia dubia in the fourth skin conditioner, as a plant extract, increased skin elasticity and more easily moisturized the skin, further improving the moisturizing effect of the muscle base solution.
As can be seen from comparative examples 10 to 12, the first humectant, niacinamide, had a good moisturizing effect; as can be seen from comparative examples 12-14, the second moisturizing agent arginine increased moisturizing effect, probably because arginine and Euglena gracilis polysaccharide had a certain coordination effect, together increasing skin moisture. As can be seen from comparative examples 14 to 16, the third moisturizing agent, sodium polyglutamate, also has certain moisturizing and hydrating effects, so that the moisture content of the stratum corneum of the skin is increased.
As is clear from comparative examples 16 to 18, the heating temperature is preferably selected so that the effective components can be sufficiently retained and the skin can be moisturized. It can be seen from comparison of example 1 and examples 19 to 20 that the particular components of each conditioner are preferred, and the temperature during the preparation is preferred, so that the moisture absorption of the skin can be better promoted, the stratum corneum can be protected, and the moisturizing effect can be further improved.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.
Claims (10)
1. The muscle foundation solution is characterized by comprising the following components in percentage by weight:
the balance of deionized water;
phase A:
0.4-5% of 1, 2-pentanediol;
0.3 to 0.8 percent of 1, 2-hexanediol;
0.22 to 8.7 percent of first humectant;
0.01 to 0.2 percent of xanthan gum;
0.32 to 0.7 percent of preservative;
3.98-9.95% of glycerin;
phase B:
acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer 0.15-0.4%;
4.4 to 9.5 percent of deionized water;
and C phase:
1.45 to 3.3 percent of second humectant;
phase D:
0.1-5% of butanediol;
PEG-60 hydrogenated castor oil 0.01-0.3%;
0.02-0.1% of ethylhexyl glycerol;
phase E:
fructus Schisandrae extract 0.001-1%;
0.001 to 0.5 percent of first antioxidant;
0.01-4% of second antioxidant;
0.01-3% of third antioxidant;
0.01-1% of a first skin conditioner;
0.01-4% of a second skin conditioner;
0.01-3% of a third skin conditioner;
fourth skin conditioner 0.01-4%;
0.01-3% of a third humectant;
the first antioxidant consists of 52-58 wt% of hydrolyzed collagen, 0.08-0.12 wt% of ethylhexyl glycerol, 3.5-4.5 wt% of butanediol, 0.8-1 wt% of phenoxyethanol and the balance of deionized water;
the second antioxidant consists of 0.09-0.11 wt% of evening primrose root extract, 0.08-0.12 wt% of citric acid, 0.15-0.25 wt% of potassium sorbate, 0.8-1.2 wt% of phenoxyethanol, 48-53 wt% of butanediol and the balance of deionized water;
the first skin conditioner consists of 0.2 to 0.3 weight percent of hydrolyzed placenta (sheep) extract and the balance of deionized water;
the second skin conditioner consists of euglena gracilis polysaccharide, polyquaternium-51, agar, phenoxyethanol, glycerol and the balance of deionized water.
2. The muscle foundation solution as claimed in claim 1, wherein the third antioxidant comprises the following components in percentage by weight:
0.2 to 0.25 percent of hydrolyzed yeast protein;
0.4 to 0.6 percent of sodium benzoate;
25-35% of glycerol;
the balance of deionized water.
3. The muscle foundation of claim 1, wherein said second skin conditioning agent comprises the following components in weight percent:
euglena gracilis polysaccharide 2.2-2.8%;
4-6% of polyquaternium-51;
0.4 to 0.6 percent of phenoxyethanol;
2.2 to 2.8 percent of agar;
40-50% of glycerol;
the balance of deionized water.
4. The muscle foundation of claim 1, wherein said third skin conditioning agent comprises the following components in weight percent:
0.7-0.9% of cortex Meliae extract;
0.7-0.8% of maltodextrin;
75-85% of glycerol;
the balance of deionized water.
5. The muscle foundation of claim 1, wherein said fourth skin conditioning agent comprises the following components in weight percent:
0.8-1.2% of Adansonia dubia seed extract;
1.4 to 1.8 percent of phenoxyethanol;
28-32% of glycerol;
the balance of deionized water.
6. The muscle base solution as claimed in claim 1, wherein the components of the first humectant comprise the following components in percentage by weight based on the total weight of the muscle base solution:
0.1-4% of nicotinamide;
0.1-4% of methyl glucitol polyether-20;
0.01 to 0.5 percent of dipotassium glycyrrhizinate;
0.01 to 0.2 percent of sodium hyaluronate.
7. The muscle foundation of claim 1, wherein the second moisturizing agent comprises the following components in percentage by weight of the total muscle foundation:
arginine 0.15-0.4%;
1.3 to 2.9 percent of deionized water.
8. The muscle foundation solution as claimed in claim 1, wherein the third humectant comprises 1-1.4 wt% of sodium polyglutamate, 15-25 wt% of butanediol, and the balance of deionized water.
9. The method of preparing a muscle base fluid according to any one of claims 1 to 8, comprising the steps of:
s1, mixing the phase A components with the balance of deionized water, heating to 75-80 ℃, and homogenizing and stirring to obtain a first mixture;
s2, mixing the components of the phase B, adding the mixture into the first mixture after uniformly mixing, homogenizing and stirring, cooling to 55-65 ℃ after uniformly stirring, and obtaining a second mixture;
s3, mixing the components in the phase C, adding the mixture into the second mixture after uniformly mixing, uniformly stirring, cooling to 35-50 ℃, adding the phase D and the phase E, and continuously and uniformly mixing to obtain a primary muscle base solution;
and S4, carrying out primary inspection, defoaming and filtering, discharging, secondary inspection, transferring and filling on the primary muscle base fluid product to obtain a finished muscle base fluid product.
10. The method of claim 9, wherein in step S3, after the temperature is reduced to 40-45 ℃, phase D and phase E are added and mixed together sequentially.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111675624.XA CN114159333B (en) | 2021-12-31 | 2021-12-31 | Myobase liquid and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111675624.XA CN114159333B (en) | 2021-12-31 | 2021-12-31 | Myobase liquid and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114159333A true CN114159333A (en) | 2022-03-11 |
CN114159333B CN114159333B (en) | 2023-11-24 |
Family
ID=80488914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111675624.XA Active CN114159333B (en) | 2021-12-31 | 2021-12-31 | Myobase liquid and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114159333B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115177573A (en) * | 2022-08-12 | 2022-10-14 | 植物医生(广东)生物科技有限公司 | Eye muscle base solution and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109394653A (en) * | 2018-12-29 | 2019-03-01 | 杭州菲丝凯化妆品有限公司 | A kind of stoste and preparation method thereof |
CN110613638A (en) * | 2019-10-19 | 2019-12-27 | 浙江英树生物科技有限公司 | Hyaluronic acid moisturizing and repairing foundation liquid and preparation method thereof |
CN110693807A (en) * | 2019-11-16 | 2020-01-17 | 浙江英树生物科技有限公司 | Skin bottom essence and preparation method thereof |
-
2021
- 2021-12-31 CN CN202111675624.XA patent/CN114159333B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109394653A (en) * | 2018-12-29 | 2019-03-01 | 杭州菲丝凯化妆品有限公司 | A kind of stoste and preparation method thereof |
CN110613638A (en) * | 2019-10-19 | 2019-12-27 | 浙江英树生物科技有限公司 | Hyaluronic acid moisturizing and repairing foundation liquid and preparation method thereof |
CN110693807A (en) * | 2019-11-16 | 2020-01-17 | 浙江英树生物科技有限公司 | Skin bottom essence and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
"肽丽思黄金蛋白肽 二重奏焕亮弹滑少女肌", pages 1 - 2, Retrieved from the Internet <URL:http://www.zguonew.com/10158.html> * |
广州远想生物科技有限公司: "伊肤泉莱菲思弹润紧致安瓶精华液", pages 2, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakanHis.html?prodId=20210119150146chwub&gb=G> * |
浙江英树生物科技有限公司: "英树羊胎素胶原保湿精华水", pages 3, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=885446828072370176&gb=G> * |
浙江英树生物科技有限公司: "英树羊胎素胶原精华面膜", pages 3, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=888748605903470592&gb=G> * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115177573A (en) * | 2022-08-12 | 2022-10-14 | 植物医生(广东)生物科技有限公司 | Eye muscle base solution and preparation method thereof |
CN115177573B (en) * | 2022-08-12 | 2023-03-14 | 植物医生(广东)生物科技有限公司 | Eye muscle base solution and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114159333B (en) | 2023-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107334726B (en) | Acne-removing composition and preparation method and application thereof | |
CN110693807B (en) | Skin bottom essence and preparation method thereof | |
KR102265730B1 (en) | cosmetic composition for skin wrinkle improvement and whitening facial skin | |
CN110664685B (en) | Essence emulsion for improving anti-glycation effect of skin and preparation method thereof | |
CN113304075B (en) | Glacier rock cleaning oil control mud film and preparation method thereof | |
CN113786376B (en) | Eye cream composition with eye pattern removing effect and preparation method thereof | |
CN113398016A (en) | Skin soothing and repairing composition and cosmetic composition | |
CN111329802A (en) | Skin moisturizing lotion and preparation method thereof | |
CN109330954B (en) | Whitening skin brightening lotion, preparation method thereof and tyrosinase inhibitor | |
CN114848541A (en) | Anti-aging and wrinkle-removing composition and preparation method thereof, and cosmetic and preparation method thereof | |
CN110721148A (en) | Multidirectional pulling and tightening polypeptide essence and preparation method thereof | |
CN111467271A (en) | Skin care product containing acetylated hyaluronic acid | |
CN111920730A (en) | Repairing moisturizing cream and preparation method thereof | |
CN107802538B (en) | Anti-aging composition and cosmetic containing same | |
CN114224779A (en) | Eye repair composition and application thereof | |
CN112618457A (en) | Chloasma-removing composition and preparation method and application thereof | |
CN108451893A (en) | A kind of toner and preparation method thereof with long-acting moisture-keeping efficacy | |
CN113768853B (en) | Whitening and freckle-removing composition, and preparation method and application thereof | |
CN112773761B (en) | Cosmetic composition, essence and preparation method thereof | |
CN110693778A (en) | Face cream and production process thereof | |
CN114159333B (en) | Myobase liquid and preparation method thereof | |
CN112120949B (en) | Water-light moisturizing essence and preparation method thereof | |
CN113081942A (en) | Multi-dimensional hydration cream containing apple stem cells | |
CN114288201B (en) | Composition for removing pouch and fading black eye, and preparation method and application thereof | |
CN113786361B (en) | Eye cream composition with pouch removing effect and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |